Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche India's Efforts To Curb Fake Drugs Gain Popularity

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - While the global pharmaceutical industry struggles to arrive at a consensus on a new definition of counterfeit drugs, pharmaceutical company Roche India has introduced a cost-effective technology to tackle the problem called 'mass serialisation' that is fast gaining popularity among customers, say company officials

You may also be interested in...



Roche India MD Girish Telang On Modifying Business Plans In India According To The Environment: An Interview With PharmAsia News

Roche India Managing Director Girish Telang has two difficult issues to handle. On the one hand, Telang has to work closely with his global team to develop the market for Roche in India and at the same time he has to ably fend off objections raised for Roche products through contentious patent battles with Indian companies. In an interview with PharmAsia News, Dr Telang outlines his concerns and reveals how India is placed to take his company's plans forward.

Roche India MD Girish Telang On Modifying Business Plans In India According To The Environment: An Interview With PharmAsia News

Roche India Managing Director Girish Telang has two difficult issues to handle. On the one hand, Telang has to work closely with his global team to develop the market for Roche in India and at the same time he has to ably fend off objections raised for Roche products through contentious patent battles with Indian companies. In an interview with PharmAsia News, Dr Telang outlines his concerns and reveals how India is placed to take his company's plans forward.

Roche Gears Up To Launch Actemra In India; Lines Up More Clinical Research

Company has obtained product registration from India’s drug comptroller general, with launch of the RA product expected within the next three months.

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel